Companies › OsteoRemedies
1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| REMEDY SPECTRUM IM Spacer Nail PMMA spacer nail laden with gentamicin and vancomycin | – | Phase 2 | Periprosthetic Joint Infection | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06428448 | REMEDY SPECTRUM IM Spacer Nail | Phase 2 | Periprosthetic Joint Infection | Infectious disease | Aug 2027 |
No annotated target.
–
Biothervax Shenzhen Shenxin Biotechnology Jiangsu ProteLight Pharmaceutical & Biotechnology Catalysis InventVacc Biologicals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.